Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review
Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review
Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review
Submitted by
admin
on February 21, 2017 - 11:34am
Source:
Endpoints
News Tags:
Pfizer
inotuzumab ozogamicin
B cell acute lymphoblastic leukemia
priority review
FDA
Headline:
Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review
Do Not Allow Advertisers to Use My Personal information
